nuclear receptor subfamily 1 group H member 3Genealiases: LXR-a · LXRA · RLD-1
Q-omics provides the consensus-scored NR1H3 profile across patient tissues and cancer cell-line models. NR1H3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NR1H3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NR1H3 RNA expression shows 17,354 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, KIRC, and ACC as cancer lineages where NR1H3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR1H3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR1H3 survival associations across molecular data types. NR1H3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR1H3 RNA expression–survival associations across cancer types. High NR1H3 expression shows unfavorable associations in ACC and LIHC, but favorable associations in SKCM, HNSC, BLCA and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NR1H3 RNA expression.
This table summarizes NR1H3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NR1H3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR1H3 shows lower tumor expression in THCA, BRCA and LUSC and higher tumor expression in KIRC, STAD and LIHC. The KIRC box plot shows higher NR1H3 RNA expression in tumor versus normal tissue (log2 FC = +1.409, t-test p < 0.001).
This table shows molecular features associated with NR1H3 in patient tissues and cancer cell lines. In patient samples, NR1H3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NR1H3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
